Fundamentals of Liver Disease - Hepatitis C 2.0

DESCRIPTION
There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front-line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

KEY TOPIC AREAS
HCV: Epidemiology and Screening
Patient with New Diagnosis of HCV (anti-HCV positive)
Assessing Severity of Liver Disease in HCV
Management of the Patient with Chronic HCV
Management of the Chronic HCV Patient with Co-Morbid and Other Conditions
Antiviral Treatment of the Patient with HCV Infection
Management of Patients with HCV who have Achieved a Virological "Cure"
The Pediatric Patient with HCV

Release date: February 26, 2021
Expiration date: February 25, 2024
Time to complete each module: 30 minutes

CREDITS OFFERED

Continuing Education credits have expired. You may review this course but the AASLD is not able to offer credits at this time.

COMPONENTS

Online presentations comprised of:
-8 online interactive, narrated modules 15 to 20 minutes in length
-Pre- and post-test questions for each module
-Evaluation for CME or CE credit offering 

DIRECTIONS
Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

COPYRIGHT 
All faculty in this activity have given their permission for publication ©2021 AASLD. 

CONTACT INFORMATION 
For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

Learning Objectives:
• Identify patients with liver disease
• Apply diagnostic tests appropriately
• Discuss important counseling
• Recognize treatment/referral priorities
• Identify first line therapies for different liver diseases
• Refer to specialist in a timely and appropriate fashion

This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

Hepatologists
Gastroenterologists
Nurses
Nurse Practitioners
Pharmacists
Physician Assistants
Transplant Coordinators
Surgeons
Fellows/Trainees
Primary Care Physicians
Other healthcare providers

CREDITS OFFERED 
Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™ 
Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points
Continuing Education (CE): For a maximum of 4.00 Contact Hours

ACCREDITATION AND DESIGNATION STATEMENTS 
Continuing Medical Education (CME) 
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Education (Nursing Contact Hours)  
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CLAIMING CME CREDITS 
Physicians and other health care professionals for a maximum of 4.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by February 25, 2024. 

CLAIMING CE CREDITS
Nurses for a maximum of 4.00 contact hours for this enduring continuing education material must be completed by February 25, 2024. 

CLAIMING ABIM MOC POINTS  
Physicians seeking ABIM MOC credit must complete the enduring material by February 25, 2024. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through February 2024 for individuals who successfully complete MOC.

HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

             o    Complete the pre-tests

             o    Watch video presentations

             o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

             o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

MOC points are available for ABIM board certified physicians only.

DISCLOSURE OF CONFLICTS OF INTEREST 
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

John W. Ward, MD
Faculty
General non-binding support: Abbott, Roche, AbbVie, Siemens, AASLD, EASL, Zydus Cadilla, Cepheid, Asian Liver Center, John Martin Foundation, Gilead Sciences, US CDC, PHARCO and individuals

Nancy Reau, MD, FAASLD
Faculty
Grant/Research Support: AbbVie, Gilead Sciences
Faculty/Advisory Committee or Review Panels: AbbVie, Gilead Sciences

Jordan J. Feld, MD, MPH, FAASLD
Faculty
Grant/Research Support: AbbVie, Eiger, Enanta, Gilead Sciences, Janssen and Wako/Fujifilm
Faculty/Advisory Committee or Review Panels: AbbVie, Arbutus, Eisai, Gilead Sciences, GSK and Roche

Sanjeev Arora, MD, FAASLD
Faculty
Nothing to disclose

Raymond T. Chung, MD, FAASLD
Faculty
Grant/Research Support: AbbVie, Gilead Sciences, Merck, BMS, Janssen, Boehringer and Roche

Jennifer Price, MD, PhD
Faculty
Grant/Research Support: Gilead Sciences and Merck
Consulting: Theratechnologies
Ownership Interest (Spouse): AbbVie, Bristol-Myers Squibb, Johnson and Johnson and Merck

Michael W. Fried, MD, FAASLD
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and multiple NIH Grants
Consulting: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen and Merck

Andrew J. Muir, MD, FAASLD
Grant/Research Support: AbbVie, Gilead Sciences and Merck
Faculty/Advisory Committee or Review Panels: AbbVie and Gilead Sciences

Kathleen B. Schwarz, MD, FAASLD
Grant/Research Support: NIDDK, Roche/Genentech and Gilead Sciences
Consulting: Sarepta, Up-to-Date and Mirium 

Lauren A. Beste, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose 

Amanda J. Chaney, DNP, APRN, FNP-BC
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Royalties: Springer Publishing-Author 

Rena Fox, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Grant/Research Support: Gilead Sciences

Leslie Hayes, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose 

Sonal Kumar, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
Speaker's Bureau: Gilead Sciences and AbbVie
Grant/Research Support: Gilead Sciences, AbbVie and Intercept

Adam Mikolajczyk, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Amol Rangnekar, MD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Raj Vuppalanchi, MD, FAASLD 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

Susan Zapatka, DNP 
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Dominique Clayton 
AASLD Staff
Nothing to disclose

Denise Seise
AASLD Staff
Nothing to disclose

Sheryl Morgan 
Amedco LLC Staff
Nothing to disclose

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support:
No commercial support was received for this enduring material activity.